{
    "2019-12-09": [
        [
            {
                "time": "2020-12-09",
                "original_text": "智飞生物实控人转让1.05%股份引入战略投资者，为优化股权结构减持股份。",
                "features": {
                    "keywords": [
                        "智飞生物",
                        "实际控制人",
                        "大宗交易",
                        "股份转让",
                        "战略投资者"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-12-09",
                "original_text": "智飞生物今日大宗交易成交1680万股，成交价41.3元折价10.18%。",
                "features": {
                    "keywords": [
                        "智飞生物",
                        "大宗交易",
                        "成交价",
                        "折价"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2020-12-09",
                "original_text": "A股共发生74宗大宗交易成交21.39亿元（12月9日）。",
                "features": {
                    "keywords": [
                        "A股",
                        "大宗交易",
                        "成交额"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "整体市场"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2020-12-09",
                "original_text": "智飞生物现四笔大宗交易，折价约10%成交额近7亿元。",
                "features": {
                    "keywords": [
                        "智飞生物",
                        "大宗交易",
                        "折价",
                        "成交额"
                    ],
                    "sentiment_score": -0.2,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2020-12-09",
                "original_text": "太平洋医药：智飞生物重磅产品获批在即，管线价值存预期差。",
                "features": {
                    "keywords": [
                        "智飞生物",
                        "重磅产品",
                        "获批",
                        "管线价值"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2020-12-09",
                "original_text": "国盛医药张金洋团队：医药行业2020年度策略——与势偕行，因势而动——医药大变革新时代淘汰赛下的战略选择。",
                "features": {
                    "keywords": [
                        "医药行业",
                        "年度策略",
                        "大变革",
                        "战略选择"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}